Continued PGN-EDODM1 treatment for myotonic dystrophy type 1
Checks lasting safety of PGN-EDODM1 for myotonic dystrophy type 1.
Key facts
- Who runs it
- PepGen Inc
- Where
- Canada3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 48 people, planned
- Started
- 23 Dec 2025
- Expected to end
- Jan 2029
- Type of study
- Interventional
- Treatments tested
- PGN-EDODM1
- Record updated
- 30 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with myotonic dystrophy type 1 (DM1) who have completed an earlier study with PGN-EDODM1. It studies the long-term safety of PGN-EDODM1.
- Sex
- All sexes can join.
- Disease stage
- Myotonic dystrophy type 1 (DM1).
- Earlier treatment
- People must have completed a prior study with PGN-EDODM1. People cannot join if they used another experimental drug, device or product within 30 days or 5 half-lives before study entry, whichever is longer.
Main reasons for not taking part
- Abnormal lab test results at screening that the study doctor considers important
- Use of another experimental drug, device or product (other than PGN-EDODM1) within 30 days or 5 half-lives before study entry, whichever is longer
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Participant has completed a prior study with PGN-EDODM1
Who cannot take part
- Use of an investigational drug (other than PGN-EDODM1), device, or product, within 30 days or 5 half-lives of the study drug (whichever is longer) prior to study entry
- Abnormal laboratory tests at screening considered clinically significant by the Investigator
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.
The group in the trial
- PGN-EDODM1Treatment being tested
Participants will receive doses of PGN-EDODM1 once every 4 weeks (Q4W)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
- Plain-language title
- Continued PGN-EDODM1 treatment for myotonic dystrophy type 1Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 30 March 2026